IBDEI0A6 ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,4523,1,3,0)
 ;;=3^SCC Anal Skin
 ;;^UTILITY(U,$J,358.3,4523,1,4,0)
 ;;=4^C44.520
 ;;^UTILITY(U,$J,358.3,4523,2)
 ;;=^5001057
 ;;^UTILITY(U,$J,358.3,4524,0)
 ;;=C44.521^^21^281^2
 ;;^UTILITY(U,$J,358.3,4524,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4524,1,3,0)
 ;;=3^SCC Skin Breast
 ;;^UTILITY(U,$J,358.3,4524,1,4,0)
 ;;=4^C44.521
 ;;^UTILITY(U,$J,358.3,4524,2)
 ;;=^5001058
 ;;^UTILITY(U,$J,358.3,4525,0)
 ;;=C44.529^^21^281^9
 ;;^UTILITY(U,$J,358.3,4525,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4525,1,3,0)
 ;;=3^SCC Skin Oth Part of Trunk
 ;;^UTILITY(U,$J,358.3,4525,1,4,0)
 ;;=4^C44.529
 ;;^UTILITY(U,$J,358.3,4525,2)
 ;;=^5001059
 ;;^UTILITY(U,$J,358.3,4526,0)
 ;;=C44.622^^21^281^15
 ;;^UTILITY(U,$J,358.3,4526,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4526,1,3,0)
 ;;=3^SCC Skin Right Upper Limb
 ;;^UTILITY(U,$J,358.3,4526,1,4,0)
 ;;=4^C44.622
 ;;^UTILITY(U,$J,358.3,4526,2)
 ;;=^5001070
 ;;^UTILITY(U,$J,358.3,4527,0)
 ;;=C44.629^^21^281^6
 ;;^UTILITY(U,$J,358.3,4527,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4527,1,3,0)
 ;;=3^SCC Skin Left Upper Limb
 ;;^UTILITY(U,$J,358.3,4527,1,4,0)
 ;;=4^C44.629
 ;;^UTILITY(U,$J,358.3,4527,2)
 ;;=^5001071
 ;;^UTILITY(U,$J,358.3,4528,0)
 ;;=C44.722^^21^281^14
 ;;^UTILITY(U,$J,358.3,4528,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4528,1,3,0)
 ;;=3^SCC Skin Right Lower Limb
 ;;^UTILITY(U,$J,358.3,4528,1,4,0)
 ;;=4^C44.722
 ;;^UTILITY(U,$J,358.3,4528,2)
 ;;=^5001082
 ;;^UTILITY(U,$J,358.3,4529,0)
 ;;=C44.729^^21^281^5
 ;;^UTILITY(U,$J,358.3,4529,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4529,1,3,0)
 ;;=3^SCC Skin Left Lower Limb
 ;;^UTILITY(U,$J,358.3,4529,1,4,0)
 ;;=4^C44.729
 ;;^UTILITY(U,$J,358.3,4529,2)
 ;;=^5001083
 ;;^UTILITY(U,$J,358.3,4530,0)
 ;;=C44.82^^21^281^10
 ;;^UTILITY(U,$J,358.3,4530,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4530,1,3,0)
 ;;=3^SCC Skin Overlapping Sites
 ;;^UTILITY(U,$J,358.3,4530,1,4,0)
 ;;=4^C44.82
 ;;^UTILITY(U,$J,358.3,4530,2)
 ;;=^5001089
 ;;^UTILITY(U,$J,358.3,4531,0)
 ;;=L57.8^^21^281^22
 ;;^UTILITY(U,$J,358.3,4531,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4531,1,3,0)
 ;;=3^Skin Changes d/t Chr Exposure to Nonionizing Radiation
 ;;^UTILITY(U,$J,358.3,4531,1,4,0)
 ;;=4^L57.8
 ;;^UTILITY(U,$J,358.3,4531,2)
 ;;=^5009226
 ;;^UTILITY(U,$J,358.3,4532,0)
 ;;=L27.0^^21^281^23
 ;;^UTILITY(U,$J,358.3,4532,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4532,1,3,0)
 ;;=3^Skin Eruption,Generalized d/t Drugs/Meds Taken Internally
 ;;^UTILITY(U,$J,358.3,4532,1,4,0)
 ;;=4^L27.0
 ;;^UTILITY(U,$J,358.3,4532,2)
 ;;=^5009144
 ;;^UTILITY(U,$J,358.3,4533,0)
 ;;=L27.1^^21^281^24
 ;;^UTILITY(U,$J,358.3,4533,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4533,1,3,0)
 ;;=3^Skin Eruption,Localized d/t Drugs/Meds Taken Internally
 ;;^UTILITY(U,$J,358.3,4533,1,4,0)
 ;;=4^L27.1
 ;;^UTILITY(U,$J,358.3,4533,2)
 ;;=^5009145
 ;;^UTILITY(U,$J,358.3,4534,0)
 ;;=L51.1^^21^281^29
 ;;^UTILITY(U,$J,358.3,4534,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4534,1,3,0)
 ;;=3^Stevens-Johnson Syndrome
 ;;^UTILITY(U,$J,358.3,4534,1,4,0)
 ;;=4^L51.1
 ;;^UTILITY(U,$J,358.3,4534,2)
 ;;=^336636
 ;;^UTILITY(U,$J,358.3,4535,0)
 ;;=L51.3^^21^281^30
 ;;^UTILITY(U,$J,358.3,4535,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4535,1,3,0)
 ;;=3^Stevens-Johnson Syndrome-Toxic Epdrml Necrolysis Overlap Syndrome
 ;;^UTILITY(U,$J,358.3,4535,1,4,0)
 ;;=4^L51.3
 ;;^UTILITY(U,$J,358.3,4535,2)
 ;;=^336637
 ;;^UTILITY(U,$J,358.3,4536,0)
 ;;=Z12.83^^21^281^19
 ;;^UTILITY(U,$J,358.3,4536,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4536,1,3,0)
 ;;=3^Screening for Malig Neop of Skin
